I was an early advocate for zinc in the context of COVID-19, having first recommended it on March 17 in The Food and Supplement Guide for the Coronavirus and providing detailed justifications for zinc dosing in the April 10 issue of this newsletter. I am also involved in the design of a clinical trial that will test a cocktail of supplements that includes high-dose zinc.
Today, New York City physicians released a preprint* providing the first direct evidence for the use of zinc in humans.
Important note: I am not a medical doctor and this is not medical advice. Please see my more detailed disclaimer at the bottom.
As NYC became the epicenter of the crisis, the hospital at New York University Langone Health began using experimental treatments that included hydroxychloroquine, azithromycin, and zinc sulfate. In this study, they retrospectively searched the electronic health records of everyone treated from March 2 to April 5. They included patients who were positive for COVID-19, hospitalized, and treated with hydroxychloroquine and azithromycin, regardless of whether they were treated with zinc, as long as they were not treated with other experimental therapies. An additional requirement was that they were released from the hospital, transferred to hospice, or died. Transfer to hospice represents transition from trying to cure the disease to caring for someone whose disease will likely lead to death.
Hydroxychloroquine was given at 400 mg once and then 200 mg/d thereafter, which is a lower dose than used in most other studies. Azithromycin was given at 500 mg/d. Zinc sulfate was given at 220 mg/d, which presumably refers to the total salt and represents 50 mg/d of elemental zinc.
They compared patients who used hydroxychloroquine and azithromycin with zinc to those who used hydroxychloroquine and azithromycin without zinc.
411 patients took all three treatments, while 521 took the two drugs without the zinc.
The use of zinc was not associated with any difference in length of hospital stay, duration of ventilation, or any specific settings used in ventilation.
However, zinc was associated with a 49% lower risk of either being transferred to hospice or dying, a 44% decreased chance of requiring invasive ventilation, and a 56% increased likelihood of being discharged from the hospital and released to home care.
Zinc sulfate treatment was started on March 25. When controlling for the date, the association with the use of ventilation was no longer statistically significant, but the association with lower hospice care or mortality and greater likelihood of going home remained significant.
Since everyone in this study was treated with hydroxychloroquine and azithromycin, two things are true:
This study provides no information about the use of these two drugs. It only provides information about the usefulness of zinc.
This study only provides evidence about the usefulness of zinc in the context of these two drugs. While I do not believe the usefulness of zinc is limited to that context and I doubt it is even enhanced by that context, that is nevertheless the context in which zinc was tested.
Since the study is not randomized, it does not provide clear cause-and-effect evidence for the usefulness of zinc.
Nevertheless, the results are very promising, and are consistent with the position I took early on in mid-March.
The authors give substantial space to the hypothesis that hydroxychloroquine acts as a zinc ionophore. I find that doubtful, as I described here. I believe that zinc alone is likely to be beneficial, which awaits testing in future studies.
Stay safe,
Chris
Please Support This Service
These research updates are made possible by purchases of The Food and Supplement Guide to the Coronavirus. The guide contains my most up-to-date conclusions about what we should be doing for nutritional and herbal support on top of hygiene and social distancing for added protection. Due to the absence of randomized controlled trials testing nutritional or herbal prevention, these are my best guesses for what is likely to work without significant risk of harm, based on the existing science.
Many people have asked why I am charging for this instead of giving it away for free, given that this is a time of crisis and people are in need.
Unfortunately, I have not been immune to the effects this virus has had on the economy. My revenue from my other offerings started falling in February, and by mid-March I had days where my revenue was zero. I have three people who work for me full-time, and I am doing everything I can to avoid laying any of them off. By mid-March I had depleted 75% of my emergency fund in order to avoid any layoffs, and without charging for the guide I would not have been able to hold out much longer.
Charging for the guide has allowed me to keep everyone working, replete some of my savings, and devote myself to researching COVID-19 full-time. As a result I now publish this daily COVID-19 Research Updates newsletter you are currently reading, am involved in the design of several clinical trials that are in the process of being submitted for registration now, and am able to continually update the guide for free whenever my research warrants it.
By purchasing the guide, you are enabling me to continue devoting my skills to the most important issue we now face. I am genuinely grateful for your contribution. You can purchase the guide using this link.
Disclaimer
I am not a medical doctor and this is not medical advice. I have a PhD in Nutritional Sciences and my expertise is in conducting and interpreting research related to my field. Please consult your physician before doing anything for prevention or treatment of COVID-19, and please seek the help of a physician immediately if you believe you may have COVID-19.
Subscribe
If you aren't subscribed to the research updates, you can sign up here.
Archive
You can access an archive of these updates here.
Comments and Questions
To leave a comment or question, please use the Facebook post for this newsletter.
*Footnotes
* The term “preprint” is often used in these updates. Preprints are studies destined for peer-reviewed journals that have yet to be peer-reviewed. Because COVID-19 is such a rapidly evolving disease and peer-review takes so long, most of the information circulating about the disease comes from preprints.